SCHEMBL4767672

SCHEMBL4767672

[c]1nc(-c2ccccc2)c(-c2ncccc2-c2ccccc2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.46
PTGS1 P23219 1/20 0.46
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
FEN1 P39748 1/20 0.35
PTPRC P08575 2/20 0.35
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
PTPN13 Q12923 1/20 0.35
KMT2A Q03164 2/20 0.34
TDP2 O95551 1/20 0.34
NSD2 O96028 1/20 0.34
ABL1 P00519 1/20 0.34
PLCG1 P19174 1/20 0.34
CES1 P23141 1/20 0.34
PAX8 Q06710 1/20 0.34
RIN1 Q13671 1/20 0.34
MEN1 O00255 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613320 0.77 NR4A2 (0.42) PTGS2PTGS1ALDH1A1HTTHSD17B10
SCHEMBL37278 0.77 PTGS2 (0.66) PTGS2PTGS1ALDH1A1HTTHSD17B10
Ammonia Solution, Strong SCHEMBL20599554 0.75 PTGS2 (0.64) PTGS2PTGS1ALDH1A1HTTHSD17B10
Phosphine SCHEMBL29108837 0.75 PTGS2 (0.64) PTGS2PTGS1ALDH1A1HTTHSD17B10
SCHEMBL30021842 0.75 PTGS2 (0.64) PTGS2PTGS1ALDH1A1HTTHSD17B10
SCHEMBL29227428 0.75 PTGS2 (0.64) PTGS2PTGS1ALDH1A1HTTHSD17B10
SCHEMBL3344343 0.75 PTGS2 (0.64) PTGS2PTGS1ALDH1A1HTTHSD17B10
SCHEMBL7647031 0.75 PTGS2 (0.58) PTGS2PTGS1ALDH1A1HTTHSD17B10
Hydrazine SCHEMBL29197518 0.74 PTGS2 (0.62) PTGS2PTGS1ALDH1A1HTTHSD17B10
Pyrazine SCHEMBL28393900 0.72 PTGS2 (0.60) PTGS2PTGS1ALDH1A1HTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713778-B1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LTD (GB) 2008-01-16 EP disclosed
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists GLAXO GROUP LIMITED (GB) 2007-03-15 US disclosed
EP-1713778-A1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LIMITED (GB) 2006-10-25 EP disclosed
WO-2005058837-A1 BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060566-A1 Benzazepine derivatives as histamine h3 antagonists HRH3, HRH4, HRH1 PTGS2 1788/4885PTGS1 1805/4885ALDH1A1 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.